Although there was no significant difference of MD2 expression between grade II and III in the dataset of CGGA, MD2 expression level was significantly increased along with the progression of gliomas from grade II to grade IV in both datasets (Figure 2A). The gene discussed is LY96; the disease is central nervous system cancer.